Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer-Reference-Cited by-同舟云学术

Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer

Published:2024-03 Issue:4 Volume:16 Page:257-266
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Bezerra de Mello Ramon Andrade¹²³^ORCID,Perez Kátia Roque³⁴^ORCID,Vazquez Thais Pérez⁵

Affiliation:

1. Department of Oncology, Oxford Cancer Center, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, OX3 7LE, Oxford, UK

2. Department of Oncology, University of Oxford, OX3 7ER, Oxford, UK

3. Post Graduation Program in Medicine, Faculty of Medicine, Nine of July University, 015250-000, São Paulo, Brazil

4. Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru

5. São Paulo Cancer Institute, University of São Paulo, São Paulo, 01246-000, Brazil

Abstract

Triple-negative breast cancer (TNBC) comprises 15–20% of all breast cancers (BC). Lacking targeted therapy options, TNBC becomes the focal point of clinical investigations aiming not only to identify drugs with enhanced response potential but also to uncover new immunological and/or metabolic pathways conducive to more effective treatments. Currently, neoadjuvant treatment for TNBC relies on standard chemotherapy in conjunction with immunotherapy, given the improved response observed with this drug combination. This review delves into the latest therapeutic updates in TNBC treatment and explores potential advancements shaping the future landscape of this disease in the neoadjuvant setting.

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2022-0277

Reference71 articles.

1. Triple-Negative Breast Cancer: Molecular Subtypes and New Targets for Therapy

2. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update

3. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

4. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

5. Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021